Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

Simona Di Giambenedetto, Antonella Castagna, Stefano Rusconi, Roberto Gulminetti, Stefano Bonora, Giovanni Mazzola, Maria E. Quiros-Roldan, Giuseppe V. De Socio, Nicoletta Ladisa, Sinibaldo Carosella, Annamaria Cattelan, Maurizio Mena, Andrea Poli, Laura Galli, Agostino Riva

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

: We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.
Lingua originaleEnglish
pagine (da-a)1256-1260
Numero di pagine5
RivistaAIDS
Volume33
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)
  • antiretroviral therapy
  • dolutegravir
  • dual therapy
  • switch strategy

Fingerprint

Entra nei temi di ricerca di 'Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy'. Insieme formano una fingerprint unica.

Cita questo